Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Endpoint Security: How It Protects Your Business from Cyber Threats
In today digital landscape businesses face an increasing number of cyber threats with endpoints being a primary target Endpoint security plays a crucial role in safeguarding organizations from cyberat ...
EyePoint announces Phase 2 VERONA trial met primary endpoint
Pharmaceuticals announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an ...
GH Research announces primary endpoint met in Phase 2b trial of GH001
PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...
Yahoo Finance7d
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001) The majority of the patients ...
Daily4h
Evolocumab Shows Sustained Cardiovascular Benefits in Older Patients With ASCVD: FOURIER Trial Findings
Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...
Healio4d
Duravyu for DME meets primary, secondary endpoints in phase 2 trial
Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.
Healio3d
Blood test may improve decision-making in Alzheimer’s disease
A blood-based biomarker test may be a reliable method for predicting or ruling out Alzheimer’s disease-related pathology and ...
Morningstar6d
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind ...
TCTMD4d
Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab
Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...
The Bakersfield Californian4d
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the ...
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...
Yahoo Finance7d
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001) The majority of the patients ...